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ABSTRACT 
AIM OF THE STUDY: 
This study compares the pre-emptive analgesic effects of oral Gabapentin and oral Clonidine on 
intubation response and post-operative analgesic requirement for patients undergoing Laparoscopic 
Cholecystectomy. 
ABSTRACT: 
Pre-emptive Analgesia has been reported to provide good perioperative outcomes using various 
methods, in attenuating the hemodynamic response to intubation & laryngoscopy and decreasing the 
post-operative analgesic requirement in patients undergoing Laparoscopic Cholecystectomy. There 
has been very few studiesusing oral gabapentin and oral clonidine as pre-emptive analgesia  In this 
study  we randomly selected 75 patients and divided into three groups. Group A received oral 
Gabapentin of 900 m , Group B received oral Clonidine of 0.2 mg and Group C received oral Vitamin 
C , 90 minutes prior to induction.The primary outcomes were to measure the hemodynamic stress 
response by Heart Rate, Systolic blood pressure, Diastolic blood pressure, Mean arterial 
pressure during intubation and post-operative  VAS score and Analgesic requirement. 
RESULTS: 
Heart rate, Systolic blood pressure, Diastolic blood pressure, Mean arterial pressure changes 
were lower with Clonidine than Gabapentin than placebo group 
Post-operative VAS score and analgesic requirement were found to be much lower in 
Gabapentin Group than clonidine than placebo group. 
CONCLUSION: 
From my study, I conclude that both Gabapentin and Clonidine when given orally 90 minutes 
prior to induction were found to be effective as good pre-emptive analgesics in decreasing the 
hemodynamic stress response to laryngoscopy and intubation , with the added benefit p of 
providing post-operative pain relief also. Clonidine was found to be slightly better than 
Gabapentin in attenuating hemodynamic stress response to laryngoscopy and intubation. 
Gabapentin was found to be slightly better than clonidine in providing post-operative pain 
relief. 
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INTRODUCTION 
Laryngoscopy and endotracheal intubation are powerful stimuli which can 
increase the sympathetic activity leading to tachycardia, hypertension and 
dysrhythmias.34,20 These hemodynamic changes are associated with the release of 
catecholamine (cortisol, epinephrine and nor-epinephrine), which are prone to get 
aggravated with laparoscopy using CO2 pneumo-peritoneum concomitantly. 
Pre-emptive analgesia with Gabapentin and Clonidineblunt the stress response 
to anaesthetic and surgical stimuli, also reduce the narcotic and anaesthetic doses in 
the peri-operative period. This feature makes Clonidine or Gabapentin useful in the 
anaesthetic management of patients undergoing laparoscopic surgeries.  
Accordingly, this study was designed to compare the pre-emptive analgesia of 
oral Gabapentin and Clonidine in attenuating the haemodynamic response to 
intubation and decreasing the post-operative pain in patients undergoing laparoscopic 
cholecystectomy. 
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AIM OF THE STUDY 
To compare the effects of Oral Gabapentin vs Oral Clonidine given as a pre-
emptive analgesic, on attenuation of the intubation response and postoperative 
analgesic requirement in patients undergoing Laparoscopic Cholecystectomy. 
 
Objectives: 
  
 Haemodynamic changes with intubation 
 Post-operative VAS score  
 Post-operative analgesic requirement 
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PRE-EMPTIVE ANALGESIA 
In 1913, the concept of Prevention of Pain, Pre-emptive Analgesia was first 
introduced by Crile.34 
The first study on pre-emptive analgesia was published by Woolf and Wall in 
1986.56, 57 
Pre-emptive analgesia (PEA), the concept which initiated during the time of 
growing appreciation on features of pain pathway, is by administering effective 
analgesia prior to the anaesthetic and surgical trauma 56 Therapeutic choices for pre-
emptive analgesia include almost all analgesic modalities and drugs individually or in 
combination. The primary assumption is that a pre-treatment approach diminishes 
acute pain scores and analgesic requirements more than post- surgical approach. 
Timing of the initiation and ability to inhibit sensitization are essential to the use of 
pre-emptive analgesia.53 
Pre-emptive Analgesia is defined as “Treatment that prevents establishment 
of central sensitization caused by incisional and inflammatory injuries; the analgesic 
effect starts before incision and covers both the period of surgery and the initial 
postoperative period.” 
The balance between incisional injury and inflammatory injury depends on the 
nature of surgery; with inflammatory injury being a dominant factor.58,19 
Pre-emptive analgesia inhibits (or reduces) pathologic pain that is different 
from physiologic pain in numerous ways.15 It is excessive (in intensity and spread) 
and can be activated by low-intensity stimuli (allodynia, hyperalgesia) and 
hyperpathia.15 
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CONCEPT OF PRE-EMPTIVE ANALGESIA: 
Pain sensation from damaged tissues, recruits a cascade of adaptations in 
somatosensory system leading to amplified responsiveness of both central and 
peripheral neurons. Because of these adaptations, response to subsequent stimuli is 
increased, thus escalating pain. 
In pre-emptive analgesia, anti nociceptive treatment is started before and is 
operational during surgical procedure, so that the physiological consequences of 
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nociceptive transmission or reduced. Because of this protection on nociceptive 
pathways, pre-emptive analgesia is more effective than analgesic treatment initiated 
after surgery. Thereby pre-emptive analgesia reduces immediate postoperative pain 
and prevents the development of chronic pain. 
SCIENTIFIC RATIOANLE: 
Tissue damage is perceived by free nerve endings of peripheral nerves (first 
order neurons) called nociceptors. They act as transducers converting mechanical, 
chemical and thermal injury into electrical signals, which are then transmitted to 
dorsal horn neurons(second order neurons)in spinal cord.Nociceptors are of different 
forms; Myelinated Aδ nociceptors conduct rapid sharp well localised pain called first 
pain; Unmyelinated C nociceptors conduct duller, slower onset and poorly localised 
pain called second pain. 
Dorsal horn contains two groups of neuron. Nociceptive specific (NS) neurons 
respond only to noxious stimuli from Aδ and C nociceptors.Wide dynamic range 
(WDR) neurons respond to both noxious stimuli and non noxious stimuli from Aβ 
fibres(i.e touch).Activity of WDR neurons depend on excitatory and inhibitory input 
from nociceptive and non nociceptive peripheral nerve fibres and descending inputs 
from supraspinal sites. 
Tissue damage produces local inflammation by release of pain promoting 
substances (i.e. Substance P, prostaglandin, serotonin, bradykinin and histamine). 
They lead to peripheral sensitization of nociceptors which produce altered 
transduction and increased conduction of noxious impulses to CNS. Transmission of 
noxious stimuli from nociceptors to dorsal horn neurons(NS &WDR) effects in 
altered receptiveness of these neurons. Stimuli from Aδ and C fibres are amplified 
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(i.e. Hyperalgesia)and stimulus from Aβ fibres are misinterrupted. (i.e. allodynia). 
This is central sensitization. 
Pre-emptive analgesia helps to prevent the neurological and biochemical 
consequences of noxious input to central nervous system. 
CONCEPT OF PRE-EMPTIVE ANALGESIA15: 
 Central hyperexcitability— exaggerated and prolonged responsiveness of 
neurons to normal afferent input after tissue damage 
 Pre-incisional treatment — treatment that starts before an initial surgical 
incision 
 Post-incisional treatment — treatment that starts immediately after the end 
of operation. 
Noxious stimuli that are sufficient to induce injury to the tissue can cause 
hypersensitivity, hyperalgesia, allodyniaand abnormal paresthesia, which leads to 
initiation of pain by non-invasive stimulus. This is attributed to the combination of 
peripheral sensitization (associated with the lowered threshold of nociceptors) and 
central sensitization (related to the increased excitability of central nervous system). 
These sensory disturbances are considered to the cause for persistent 
postoperative pain. Local tissue damage and inflammation along with various 
sympathetic terminal-derived chemical mediators (hydroxyl ions, noradrenaline, 
potassium ions, prostaglandins, purines, bradykinin, histamine, cytokines, 5-HT, 
leukotrienes, nerve growth factor and neuropeptides) are responsible for peripheral 
sensitization, which increases the excitability of dorsal horn neurons followed by 
central sensitization.  
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As soon as central sensitization is established, signals are transferred via Aβ 
fibers from low-threshold mechanoreceptors and are perceived as pain at dorsal horn 
neurons with high excitability. As Aδfibers and C fibers from the nociceptors are 
below peripheral sensitization, pain will be greater and are unremitting. Once central 
sensitization is established, patients respond poorly to analgesics. 
Pre-emptive analgesia reduces postoperative pain by inhibiting central 
sensitization even before surgery, if pain is provided before surgery; central 
sensitization is inhibited and preventing postoperative hyperesthesia. Instead, if only 
postoperative analgesic treatment is delivered, surgery-induced central sensitization is 
established. Hence, postoperative hyperesthesia is only inhibited for the time being. 
 Many new studies on pre-emptive analgesia were published and it was found 
essential to consider the inflammatory injury for pain mechanism. 
GOALS:  
1. Reduction in acute pain after tissue injury. 
2. Inhibits pain related pathologic modulation of central nervous system. 
3. Prevents persistence of post-operative pain and development of chronic 
pain 
4. Effective pre-emptive analgesia uses multiple pharmacological agents 
to diminish nociceptor activation by decreasing receptor activation and 
by inhibiting the activation of pain neurotransmitters. 
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HISTORY OF LARYNGOSCOPY AND INTUBATION 
 In 1854, a Spanish vocal pedagogist, Manuel Garcia (1805-1906) was the 
first man to visualize the active glottis in a human being. 
 On 23rd April 1895, the first direct laryngoscopy was performed by Alfred 
Kirsten. 
 William Macewen (1848-1924) a Scottish Surgeon, conveyed orotracheal 
intubation as an alternative to tracheostomy. 
 In 1913 Chevalior Jackson, has been recognised with high success in direct 
laryngoscopy. 
 Sir Robert Macintosh (1897-1989), familiarised his new curved 
laryngoscopy blade in 1943. 
 In 1940, Reid and Brace, was first to describe haemodynamic response to 
direct laryngoscopy and endotracheal intubation34. 
RESPONSE TO LARYNGOSCOPY 
The induction of anaesthesia, laryngoscopy, tracheal intubation and surgical 
stimulation provoke cardiovascular responses leading to alteration in heart rate, 
cardiac rhythm and blood pressure. The response starts in 5 seconds, peaks in 1-2 
minutes and returns to baseline in 5 minutes. 
This sympatho-adrenal response is of little importance in healthy patients but 
dangerous in patients with hypertension, coronary artery disease, cerebrovascular 
disease, intracranial pathology, and hyperreactive airways, so it should be 
attenuated.44,22 
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Prof. King et al., in 1951 documented myocardial ischemic changes following 
laryngoscopy and intubation with increase in systolic blood pressure upto 40 mmHg 
even in normotensive patients. 
 
 
ANATOMY AND NERVE SUPPLY OF LARYNX 
The pharynx is divided into nasopharynx, oropharynx and laryngopharynx. 
The oropharynx from laryngopharynx is separated by epiglottis. 
The Hard and Soft palate is supplied by palatine branch of the trigeminal 
nerve.The anterior 2/3rd of the tongue is supplied by the lingual nerve and the 
posterior 1/3 rd of the tongue and the roof of the pharynx are supplied by 
glossopharyngeal nerve. 
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The pharyngeal surface of the epiglottis is supplied by the glossopharyngeal 
nerve and the laryngeal surface is supplied by the vagus. The sensory supply of the 
supraglottic area is by the internal branch of superior laryngeal nerve. The motor 
branch of the recurrent laryngeal nerve supplies all the intrinsic muscles of the larynx 
except the cricothyroid, which is supplied by the external laryngeal nerve and the 
sensory branches of the recurrent laryngeal nerve supply the mucosa of the larynx 
below the vocal cords. 
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 PHYSIOLOGY OF THE STRESS RESPONSE: 
The larynx is a highly innervated sensory structure, so laryngoscopy and 
tracheal intubation stimulates these structures leading to stress response. 
Hemodynamic stress response to laryngoscopy and tracheal intubation 
augments as increase in heart rate and blood pressure due to reflex sympathetic 
discharge.10 The subsequent rise in rate / pressure product may result in a myocardial 
oxygen demand which surpasses oxygen supply resulting in myocardial ischemia.This 
stress response starts within 5 seconds peaks within 10 minutes of intubation and 
returns to base line in 5 minutes.  
The force and duration of laryngoscopy, hypoxia, hypercarbia, stimulation of 
carina by endotracheal tube, repeated and prolonged attempts are few factors which 
affect the stress response.  
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CARDIOVASCULAR RESPONSE: 
Hypertension, tachycardia,bradycardia and dysrhythmias are mediated by 
autonomic nervous system. Hypertension, tachycardia, increase in cardiac work and 
oxygen consumption are mediated by sympathetic system via the cardio accelerator 
fibres and sympathetic chain ganglia. The polysynaptic pathway from 9th to 10th nerve 
afferents to sympathetic nervous system in the brain stem and spinal cord, results in a 
diffuse autonomic response, leading to extensive release of norepinephrine from the 
adrenergic terminals and release of epinephrine from the adrenal medulla. 
Another reason, for the hypertensive response is due to activation of renin 
angiotensin system with release of renin from the renal juxtaglomerular apparatus and 
an end organ innervated by adrenergic nerve terminals. 
Bradycardia which is caused by a rise in vagal tone in Sino Atrial node is a 
monosynaptic reflex to a noxious stimulus. 
RESPIRATORY SYSTEM 
 Possibility of Reflex glottis closure leading to laryngospasm, 
 Dead space will be decreased. 
 Airway resistance is increased 
 Bronchospasm 
STRESS RESPONSE IN PATHOLOGICAL CONDITIONS 
1. Patients with limited myocardial reserve may go for myocardial ischemia and 
failure. So it is necessary to maintain the rate and blood pressure of the patient 
within 20% of the normal value. Heart rate should be less than 110 beats per 
minute ( ischemic threshold) 
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2. Intracranial vascular anomalies can rupture. 
3. In patients with hyperactive airways bronchospasm and laryngospasm can 
occur. 
4. Laryngoscopy and intubation can increase cerebral blood flow if auto 
regulation is compromised. The resultant increase in intracranial pressure can 
lead to brainstem herniation and death. 
Hemodynamic responses to laryngoscopy, intubation and laparoscopy should 
be diminished by the appropriate premedication, smooth induction, and rapid 
intubation. However, prevention and treatment of postoperative pain still remains a 
main challenge in postoperative care in spite of major advancements in pain 
assessment and therapy.  
METHODS TO ATTENUATE INTUBATION RESPONSE 
Hypertension and tachycardia have been reported as common during 
laryngoscopy and intubation in lighter plane of anaesthesia. Acceleration in blood 
pressure and heart rate occurs most commonly from reflex sympathetic discharge 
producing excessive catecholamines, which may be lethal in patients with heart 
disease and hypertension.37, 49 
1. Maintaining a deep plane of general anaesthesia using volatile anaesthetics. This 
dose of volatile anaesthetics necessary to block the cardiovascular responses to 
endotracheal intubation may result in profound cardiovascular depression.The 
volatile agents used are Halothane, Isoflurane and Sevoflurane. 
2. Local anaesthetics: Lignocaine is used. 
a. For oropharyngeal anaesthesia as viscous gargle 
b. Spray for intratracheal anaesthesia 
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c. Intravenous 
d. Local instillation or topical spray over the vocal cords. 
e. Regional nerve blocks. 
3. Vasodilators – Nitroglycerine, sodium nitroprusside, hydralazine 
4. Magnesium sulphate 
5. Narcotics - Fentanyl, Sufentanyl,Remifentanyl, Morphine, Pethidine. 
Fentanyl is the most commonly used narcotic. It is a potent analgesic, has a short 
duration of action, and it does not increase intracranial tension with minimal 
circulatory changes. 
6. Calcium Channel blockers – Nifidipine, Nicardipine, Verapamil, Diltiazem 
7. Adrenergic blockers  
β Blockers – Metaprolol, Esmolol 
α Blocker - Phentolamine 
α and β blocker – Labetalol 
8. Central Sympatholytics – Clonidine and Dexmeditomidine. They act by reducing 
central sympathetic outflow. 
9. Sedatives and anxiolytics. 
POST OPERATIVE PAIN ASSESSMENT METHODS: 
In the post-operative period, assessing the degree of pain is very important. 
Assessing Pain is considered as an important vital sign in postoperative period. It 
must be done at regular intervals. 
Post-operative pain assessment involves educating the patients to gain 
knowledge thereby alleviating the fear and anxiety about pain, which develops a 
positive approach towards pain, thereby improving the satisfaction of the patient. 
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Pain assessment helps us to quantitate the intensity of pain, guides us to 
formulate analgesic regimen and to assess the response to treatment given. There are 
numerous methods to assess pain. These assessment methods need to be simple and 
easily understandable by the patient. 
In patients who can communicate verbally, Self report is the gold standard and 
external signs of pain or distress (crying,wincing) are minor. For patients with 
difficulty in communication and in children, nonverbal indicators (behavioural and 
sometimes physiologic) may form the principal basis of information. Commonly used 
pain scales are: 
 VISUAL ANALOG SCALE 
 NUMERICAL RATING SCALE,  
 VERBAL RATING SCALE 
 WONG BAKER FACES RATING SCALE 
VISUAL ANALOG SCALE 
Visual analog scale enables us, to assess the grade of the intensity of pain. It is 
a simple, efficient, non-invasive method. It is a 10 cm long scale with the end points 
labelled as ‘no pain’ and ‘worst possible pain’. The patient makes a mark on the scale 
at a point parallel to the intensity of pain he or she presently feels. This method of 
pain assessing scale is not useful for children, visually impaired persons and in those 
with cognitive impairment. 
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NUMERICAL RATING SCALE: 
It closely resembles Visual analogue scale with a 10 cm line with left end 
marked as zero(indicating no pain) and right end as 10( indicating worst pain)with 
numbers marked in between from 1-9, having eleven points on scale. Patient will be 
asked to point out a number on the scale corresponding to the pain he or she feels that 
moment. 
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VERBAL RATING SCALE: 
Here patients were asked to express their pain verbally as no pain, mild pain, 
moderate pain and severe pain. In this pain assessing method, Smallchange in pain 
intensity can be missed. 
 
 
WONG BAKER FACES PAIN RATING SCALE: 
It is for patients who cannot communicate and in children of 3- 7 years of age. 
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GABAPENTIN 
Gabapentin was introduced in early 1990s for the treatment of seizures. 
Gabapentin belongs to second generation anticonvulsant drug, is an analog of 
GABA12, where a GABA molecule is covalently bound to a lipophilic isobutene or 
cyclohexane ring. Later it was found to be efficient for the treatment of chronic pain 
conditions like diabetic neuropathy, post herpetic neuralgia, HIV related neuropathy, 
trigeminal neuralgia, inflammatory pain, malignant pain, and complex regional pain 
syndromes.  
Also recent evidences are favouring perioperative administration and its 
efficacy in preoperative anxiolysis, attenuation of the hemodynamic response to 
laryngoscopy and intubation, and in prevention of chronic post-surgical pain, 
postoperative nausea and vomiting, and delirium.53 
CHEMISTRY: 
Gabapentin, an inhibitory neurotransmitter,1-(amino methyl)cyclohexane 
acetic acid, is a structural analogue of GABA.53 
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Molecular formula: C9H17NO2 
Molecular weight: 171.24 
Gabapentin is freely soluble in water, white to off-white crystalline solid, 
Highly charged at physiological PH existing as a zwitterion with a pKa1 of 3.7 and a 
pKa2 of 10.7. The log of the partition coefficient at PH 7.4 is –1.25.  
For drug assay in urine and plasma, high performance liquid chromatography 
and gas chromatography are used.53 
PHARMACOKINETICS: 
All pharmacological actions are due to the activity of the parent compound, 
Gabapentin is not appreciably metabolised in humans.54 
Oral bioavailability: 
Gabapentin bioavailability is not dose dependant; i.e., as dose is increased, 
bioavailability decreases. Bioavailability of 300mg and 600 mg Gabapentin is 60% 
and 40% respectively55. Food has slight effect on the rate and extent of absorption of 
Gabapentin 
Distribution: 
Gabapentin is extensively distributed in human tissues and fluid after 
administration. Volume of distribution is 0.6- 0.81 / kg. It is not bound to plasma 
proteins. As it is highly ionised at physiological PH, concentration in adipose tissue is 
low. Gabapentin is highly lipid soluble, crosses blood brain barrier. Concentration in 
CSF is approximately 5-35% of those in plasma, whereas in brain tissue it is 80% of 
those in plasma. Peak plasma concentration is reached in 2-3 hrs after oral intake. 
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Metabolism: 
 Gabapentin is not significantly metabolized in humans. It does not induce 
hepatic microsomal enzymes. 
Elimination: 
Gabapentin is eliminated from the systemic circulation as unchanged drug in 
urine and unabsorbed drug is excreted in faces. Gabapentin elimination half-life is 5-7 
hrs in normal renal function and is unaltered by dose or following multiple dosing. 
Gabapentin elimination rate constant, plasma clearance, and renal clearance are in 
direct proportion to creatinine clearance. 
Gabapentin plasma clearance is reduced in elderly patients and in patients with 
impaired renal function. It can be cleared from plasma by hemodialysis. 
Drug interactions: 
Cimetidine, H2 receptor blockers decreases renal clearance when given 
currently.35Antacids when given concurrently, reduces the bioavailability of 
Gabapentin.38 
Special situations:  
Age: Renal clearance decreases with increasing age. Hence dose adjustment is 
required in patients who have age related decline in renal function. 
Gender: There is no significant difference in gender. Pharmacokinetic parameters are 
similar in both sexes. 
Renal insufficiency: The patients with reduced creatinine clearance are having 
increased half-life of Gabapentin. Hence dose adjustment is necessary. 
Hemodialysis: The half-life of Gabapentin is reduced in patients on dialysis. 
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Hepatic diseases: Since Gabapentin is not metabolised in humans. No study was 
performed in patients with hepatic impairment. 
Pregnancy and lactation: Gabapentin has been assigned to pregnancy category C. 
Fetotoxicity involving delayed ossification of several bones been revealed in animal 
studies. There is no controlled data in human studies, so it should be given when 
benefit outweighs risk. Gabapentin is secreted into milk, hence used only when 
benefit outweighs the risk. 
ANTINOCICEPTIVE MECHANISM: 
 
Gabapentin selectively binds to the α2δ subunit of voltage gated Calcium 
channels (found high in cerebral cortex, superficial dorsal horn, cerebellum, 
hippocampus),principally to post synaptic channels and inhibits calcium influx 
through these channels. Thereby inhibiting the evoked release of glutamate, aspartate, 
substance P, and calcitonin gene-related peptide (CGRP) from the primary afferent 
nerve fibres in pain pathway and hence a reduction in neuronal hyper excitability. 
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Also Gabapentin acts on spinal α2 Adrenoreceptor to produce analgesia by activating 
the descending spinal nor-adrenergic system by releasing noradrenaline.47, 48 
Despite intensive studies, exact mechanism of action of Gabapentin not known. 
A number of mechanisms may be involved in the actions of Gabapentin.4 
Despite its structural similarityto GABA,it does not act via mechanisms related to 
GABA3 Possible proposed mechanism: 
 
 Selective stimulation of the heterodimeric GABA B receptor which consist of 
GABA B1a and GABA B2 subunits.3,29 
 Augmentation of the N-methyl-D-aspartate (NMDA) current at GABAergic 
interneurons.14 
 Delaying a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor mediated transmission in the spinal cord.40 
 Binding to the L-a-amino acid transporter;11, 42 activating adenosine 
triphosphate sensitive Kβ (KATP) channels.27 
 activating hyperpolarization-activated cation current (Ih) channels.46 
 modulating Ca2 β current by selectively binding to [3H]Gabapentin (a radio 
ligand), the α2δ subunit of voltage-dependent Ca2 β channels(VGCCs).46, 9 
Currently, VGCC is the most likely analgesic target of Gabapentin. 
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ERIOPERATIVE BENEFITS OF GABAPENTIN 53 
All perioperative applications are “off label” (the use of drugs outside the 
terms of their licence in clinical practice) 
 in perioperative anxiolysis 
 in post-operative analgesia 
 in attenuating hemodynamic response to laryngoscopy and intubation 
 In prevents chronic post-surgical pain, post-operative nausea, vomiting and 
delirium. 
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CLONIDINE 
Clonidine, an imidazole derivative of α2 agonist was originally introduced as 
vasoconstrictor and as topical nasal decongestant. It is a selective partial agonist for α2 
Adreno receptors.17 It has variety of actions including antihypertensive effects as well 
as the ability to potentiate the effects of local anaesthetics. Clonidine can be 
administered orally, intravenously, intramuscularly, transdermally, epidurally, and 
intrathecally.17 
PHYSIOCHEMICAL PROFILE 
Clonidine hydrochloride is produced by chemical synthesis. It is an odourless, 
white crystalline powder having bitter taste. 
Molecular weight : 266.6 
PKa1 : 8.3 
Solubility in alcohol : 1 in 25 
Solubility in water : 1 in 13 
Octanol / water partial coefficient : 3.02 
Structure: 2,6, dichloro N-2 imidazolinyieldene Benzenamine hydrochloride 
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PHARMACOLOGY: 
Clonidine is a partial agonist at α adreno receptors both with in the central 
nervous system and in the periphery17. It has 300 times more affinity to α2 than for 
α1
17. In CNS, α2 receptors are located pre-synaptically (on neurons which release 
norepinephrine, epinephrine, serotonin and acetylcholine) and post synaptically (on 
noradrenergic neurons). 
PHARMACOKINETICS: 
Elimination half-life: 12-24 hrs 
Volume of distribution: 2L/kg 
Plasma protein binding: 20-40% 
Pre-systemic metabolism: 0-25% 
 Oral Bioavailability: 95%-100% 
Clonidine is lipid soluble and it readily crosses blood brain barrier. The peak 
concentration is observed at 1-3 hours after oral use and the maximal hypotensive 
effect occurs in this duration. Clonidine has varying bioavailability as an oral, 
transdermal, and parenteral preparation and can be used in epidural, intravenous, oral 
and rectal routes. 
METABOLISM  
Clonidine is approximately 50% metabolised in liver to inactive metabolites. 
Hydroxylated metabolites undergo secondary conjugation with sulphate or 
glucuronide and excreted renally. Metabolites do not have significant biological 
activity. Elimination half-life of Clonidine is about 9-12 hrs.Clearance may be 
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reduced in the renal dysfunction.Clonidine crosses the placental barrier, but doesnot 
reach concentration sufficient to harm the foetus. 
 
DOSAGE: 
Oral – bolus of 4-5 mcg/kg 
Intramuscular – bolus of 2mcg/kg 
Intravenous - bolus of 4-5 mcg/kg, continuous infusion at 2mcg/kg/hr 
Epidural – bolus of 75-40mcg/kg, continuous infusion of 12.5-70 mcg/hour 
Intrathecal- bolus of 30-225 mcg/kg, continuous infusion of 8-400mcg/day 
Peripheral nerve block- 1-2 mcg/kg 
Intra articular - 2mcg/kg 
EFFECTS ON ORGAN SYSTEM: 
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1. CARDIOVASCULAR SYSTEM: 
Administration of oral or intravenous Clonidine will cause a dose dependant 
drop in blood pressure and heart rate in both supine and standing position, orthostatic 
hypotension being more prominent. If Clonidine is administered rapidly as 
intravenous, there will be a brief pressor phase lasting less than 5 minutes with a MAP 
of less than 10 mmHg followed by hypotensive effect, which is more rapid with 
intravenous administration. The time of maximum effect (1.5-2 hrs) is similar in both 
routes. The degree of bradycardia is more marked after rapid intravenous 
administration. The extent of hypotension is also dose related and may extend for 24 
hrs after single dose of 150-300 mcg. The magnitude of hypotensive effect is more 
with hypertensive individuals than normotensive subjects. 
Stimulation of α2 adrenergic neurons in the medullary vasomotor centre and in the 
nucleus tractussolitarius, leads to inhibition of sympathetic outflow leading to 
bradycardia and hypotension. 
It decreases blood pressure from reduction of cardiac output due to reduced 
heart rate and relaxation of capacitance vessels as well as decrease in peripheral 
vascular resistance30. The pressor response with high dose of Clonidine is mediated 
by stimulation of α1 or α2adrenorecptors on vascular smooth muscles leading to 
peripheral vasoconstriction.30 
Anti arrhythmic properties: Clonidine is capable of preventing adrenaline induced 
arrhythmias during halothane anaesthesia. 
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2. RESPIRATORY SYSTEM: 
Respiratory depression is seen with massive doses. However clinically we 
never use such higher doses. Clonidine is less potent than opioids. Nebulised 
Clonidine attenuates bronchoconstriction in asthmatic patients. 
3. CENTRAL NERVOUS SYSTEM: 
 Sedation is facilitated by central α2 receptors in locus ceruleus30 
 Provides anxiolysis equivalent to Benzodiazepines. 
 Analgesia – Clonidine and Opioids act via different receptor mechanisms. 
Clonidine acts via α2 adrenoreceptors in the superficial layers of dorsal horn, 
on the sensory afferents and on descending noradrenergic fibres from the brain 
stem, thereby inhibiting the spinal transmission of noxious stimulus by 
reducing the release of substance P. 
4. RENAL SYTEM: 
Clonidine produces diuresis, possibly by: 
1. Inhibiting ADH and renin release. 
2. Increasing atrial natriuretric peptide release. 
3. Increasing GFR. 
4. Antagonising the renal tubular action of ADH. 
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5. ENDOCRINE SYSTEM: 
α2agonist prevents sympathetic adrenal flow and release of neurotransmitter at 
the neuroeffector junction. 
Endocrine effects of α2 adrenoreceptor stimulation are 
 Increase in secretion of TSH & GH 
 Decrease in secretion of ACTH & ADH 
 Inhibition of glucose stimulated insulin release by directly acting on islets 
cells of langerhan, but will not result in severe hyperglycemiaas this effect is 
transient in a clinical setting. 
6. GASTRO INTESTINAL SYSTEM: 
Stimulation of peripheral presynaptic α2 adreno-receptors, on post ganglionic 
noradrenergic or cholinergic neurons reduces salivary flow, inhibits bowel motility 
and release of gastric secretion. 
7. HEMATOLOGICAL SYSTEM: 
Clonidine produces platelet aggregation. But, this effect is largely 
compensated by the decrease in circulating catecholamines. 
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OTHER USES :17, 43, 30 
 Antihypertensive agent 
 Anaesthesia: As premedication, prolonging the action of local anaesthetic in 
neuraxial blockade, in decreasing post-anaesthetic shivering. 
 Treatment of Opioid and alcohol withdrawl 
 Glaucoma(apraClonidine and brimonidine) 
 Prophylaxis of migraine 
 For Menopausal symptoms 
 Diarrhoea in diabetic neuropathy 
 Chronic pain syndromes  
 Protection against perioperative Myocardial ischemia 
 In Tics 
 For Nicotine withdrawl 
  In Psychiatric disorders 
  Provocative test of GH secretion, for investigating short stature. 
 In the diagnosis of Pheochromocytoma 
CONTRAINDICATIONS: 
  Clonidine hypersensitivity 
 Atrioventricular node disease ( sick sinus syndrome) or bradyarrhythmia 
 In patients with cardiac pacemakers. 
 Severe cardiovascular disease 
 In hemodynamically unstable patients 
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DRUG INTERACTIONS :17 
  Clonidine interacts with Tricyclic antidepressants which possess α2 antagonist 
action, thereby blocking the antihypertensive effect of Clonidine  
ADVERSE EFFECTS:17 
 Common: 
- Sedation, dry mouth, Bradycardia, which responds to atropine, 
Hypotension, Constipation, Contact dermatitis. 
 Less common: 
- Postural hypotension, fluid retention (oedema, weight gain),  
Sleep Disturbances (insomnia, hallucinations), confusion, headache, 
impotence, Parotid pain, Depression. 
 Uncommon:  
- rash, pruritis, angioedema, hepatitis, gynacomastia, Raynaud’s 
phenomenon, thinning of hair, urinary retention, agitation. 
 Withdrawl syndrome: 
 Rapid rise in blood pressure, with headache, flushing, sweating, 
insomnia,agitation, tremor, nausea and vomiting presenting, 18-72 hours after last 
dose of Clonidine. It can be prevented bytapering Clonidine over days to weeks. It can 
be controlled by inhibiting peripheral sympathetic activity with α2adrenoreceptor 
antagonists or by reintroducing Clonidine treatment. 
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BENEFITS OF CLONIDINE AS PREMEDICATION: 
 Blunts reflex tachycardia with Orotracheal intubation 
 Reduces vasomotor liability 
 Plasma catecholamines are decreased 
 Clonidine decreases the MAC value to 50% ofinhalational agents and 
decreases analgesic requirements of opioids. 
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REVIEW OF LITERATURE 
There has been numerous studies on search for newer drugs for attenuating 
intubation response and for decreasing postoperative pain. 
1.  In 1986, Ghignone M et al, 10 studied the effects of oral Clonidine on depths 
of fentanyl anaesthesia & on cardiovascular response to laryngoscopy & 
intubation in 24 patients undergoing aorto coronary bypass surgery & 
concluded that oral Clonidine reduced the fentanyl requirement and 
prevented the haemodynamic response to intubation. 
2.  In 1993, Laurito et al 23 found that Clonidine blunted the haemodynamic 
response with respect to HR, SBP and DBP to 15 sec laryngoscopy but not to 
45 sec laryngoscopy when compared with the corresponding control group.2 
3.  In 1998, Batra YK et al, 2 studied the attenuation of heart rate and blood 
pressure response to laryngoscopy and intubation by Clonidine in forty health 
patients. Heart rate and blood pressure were significantly lower in the 
Clonidine treated group immediately after intubation. 
4.  In 2000, Matot et al 24 study shows that, in patients undergoing 
laryngoscopic or bronchoscopic procedures under general anaesthesia, 
premedication with oral Clonidine (4-4.5 µg/kg) attenuates haemodynamic 
responses. In this study, premedication with Clonidine 0.2mg administered 
90 minutes prior to surgery significantly reduced HR, DAP, SAP, MAP 
changes for 10 min after endotracheal intubation. 
5.  In 2004, Turan et al,50 performed a study by giving preoperative Gabapentin 
and its role in reducing pain score and requirement of tramadol in abdominal 
hysterectomy.The patients were monitored and found that VAS score and 
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total tramadol consumption were found to be lower in patients who received 
Gabapentin. 
6.  In 2004 Chandra Kant Pandey, MD ShioPriye, et al, 32 in 459 ASA PS I and 
II patients were randomly assigned to receive 300mg Gabapentin, 100 mg 
Tramadol, and placebo in a double blinded manner 2 hours before 
laparoscopic cholecystectomy under general anaesthesia.They concluded less 
fentanyl was consumed in the Gabapentin group than in the tramadol and 
placebo group. Sedation, nausea, retching/ vomiting was the commonest side 
effects in the Gabapentin whereas respiratory depression was the commonest 
in tramadol group and vertigo in placebo group. 
7.  In 2005, C.K. Pandey et al, 31 conducted a study about postoperative pain 
and requirement of analgesics in patients undergoing lumbar discectomy by 
giving pre-operative Gabapentin 300 mg. It was found that pain score and 
fentanyl requirement was less in patients who received Gabapentin pre-
operatively. 
8.  In 2006, Turan b, Kumaralingalou et al 51, investigated the effects of 
Gabapentin on acute postoperative pain and morphine consumption in 
patients undergoing spinal surgery. Their study showed that pre-operative 
oral Gabapentin decreased pain scores in the early post-operative period and 
post-operative morphine consumption in patients who underwent spinal 
surgery while decreasing some morphine associated side effects. 
9. In 2006, Hussain Al- mujadi et al 1conducted a study by administering 
Gabapentin 1200 mg and placebo capsules,2 hours prior to thyroidectomy 
surgery for postoperative pain,morphine requirement and its side effect. They 
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concluded that patient who received Gabapentin had decreased pain scores 
and morphine requirement with insignificant side effects. 
10.  In 2006, A.Fassoulaki et al, 7 studied the effect of Gabapentin alone on post 
laryngoscopy and tracheal intubation pressor response with forty six patients 
who underwent abdominal hysterectomy or benign diseases. They monitored 
systolic and diastolic blood pressure, heart rate before and after anaesthetic 
and 0,1,3,5,10 minutes after tracheal intubation. Conclusion of the study was 
that pressor responses could be attenuated but not the tachycardia associated 
with laryngoscopy and tracheal intubation. 
11. In 2006, Memis et al, 26 studied the effect of Gabapentin on cardiovascular 
responses to laryngoscopy and tracheal intubation in normotensive patients. 
In this study 90 ASA I patients.They concluded that oral administration of 
Gabapentin 800 mg but not 400 mg given 1 hour before operation blunted the 
arterial pressure and HR increase in the first 10 min after endotracheal 
intubation. 
12. In 2007 O Kiskira et al,21 conducted a study by using Gabapentin (800 mg) 
pre-operatively, for patients undergoing orthopaedic procedures and assessed 
the post-op pain intensity and requirement of analgesics.It was found that 
post-operative pain score and morphine requirement was lesser in these 
patients during first 24 hours. 
13. In 2009 Indira Kumari et al 16, have studied the changes in SBP, DBP, MAP 
and HR following laryngoscopy and tracheal intubation after administering 
Gabapentin 900 mg, 2 hours before induction. Significant rise in SBP,DBP, 
and MAP were observed following laryngoscopy and tracheal intubation in 
placebo group as compared to Gabapentin group. No significant change in 
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heart rate was documented in both the groups. They concluded that both 
Gabapentin and Clonidinehad effective role in blunting hemodynamic 
responses after laryngoscopy, more with Gabapentin.2 
14. In 2009, Seyed Mojtaba Marashi et al 39 , conducted a study to compare the 
efficacy of Gabapentin and Clonidineas premedication in modifying the 
hyperdynamic response following laryngoscopy and tracheal intubation, with 
75 ASA I and II patients of both sexes, of age 18-45 yrs. 
15. In 2010, Nagwa M. Doha et al, 28 investigated the efficacy of Gabapentin 
(1200 mg) regarding the requirement of analgesic intra-operatively and post-
operatively in mastectomy surgeries. Intraoperative need of anaesthetic and 
analgesic requirement was lower in those who received Gabapentin as well as 
post-operative VAS score and analgesic requirement was also reduced with 
increased incidence of dizziness. 
16. In 2011, Kamran Montazeri et al, 18  also compared the efficacy of oral 
Gabapentin and Clonidine aspremedicaion for controlling the pressor 
response to laryngoscopy and tracheal intubation, where 96 patients were 
studied. In this study they concluded, that premedication with oral 
Gabapentin 800 mg or Clonidine 0.3 mg, blunted the hyperdynamic response 
after laryngoscopy and intubation. 
17. In 2011, Usha Bafna et al, 52 did a comparison study of different doses of 
Gabapentin to attenuate the pressor response to laryngoscopy and tracheal 
intubation in normotensive patients. In this study 90 ASA I and II patients 
aged 20-60 years were taken. They concluded that Gabapentin 1000mg given 
1 hour before operation significantly attenuated the hemodynamic response in 
normotensive patients. 
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18. In 2014, Suresh K Singhal et al, 45 compared Oral Gabapentin and Clonidine 
as premedication for obtunding hemodynamic response to laryngoscopy and 
tracheal intubation. In this study 100 patients,50 of each group of ASA I and 
II patients were given oral Gabapentin 900mg and Clonidine 0.2 mg prior to 
induction and concluded that oral Clonidine compared with oral Gabapentin 
obtunded the pressor response. Also Clonidine was superior with sedation 
and anxiolysis than Gabapentin. 
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METHODS AND MATERIALS 
After obtaining approval from the Institutional Ethical Committee and written 
informed consent from all the patients, the study was conducted in RGGGH, in 
Surgical Gastroenterologist operation theatre in patients scheduled for elective 
laparoscopic cholecystectomy under general anaesthesia. 
Study design:  
Randomised, clinical study, Group A (Gabapentin) will receive 900mg Tab. 
Gabapentin, Group B ( Clonidine) receiving 0.2 mg Tab. Clonidine and Group C  
( Placebo) receiving Tab. Vitamin C . 
INCLUSION CRITERIA: 
Age  : 18 – 60 years. 
Weight : BMI < 30 Kg/m2  
American Society of anaesthesiologist physical status I & II patients. 
Surgery : Elective 
Mallampatti scores : I & II 
Patients who have given valid informed consent. 
 
EXCLUSION CRITERIA: 
Patients who are not satisfying inclusion criteria. 
Patients posted for emergency surgery 
Patients with difficult airway 
Lack of written informed consent 
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H/O seizures and any neurological deficit 
Renal or liver disease. 
Recent consumption of analgesics in past 24 hours 
Known allergy or sensitivity to the drugs. 
Ongoing therapy with sustained release opioids. 
Cases which have been converted from laparoscopic to open surgery. 
 
Sample Size Calculation 
Sample size was determined based on the study of  “Effect of oral Clonidine 
premedication on perioperative haemodynamic response and postoperative analgesic 
requirement for patients undergoing laparoscopic cholecystectomy” authored by 
Shivinder Singh et al Published in Indian J Anaesth 2011;55:26-30. 
In this study Remarkably less patients were given a single dose of meperidine 
during the first 24 hours postoperatively in the Clonidine group (72% v 32%, P < 
0.05). and showing a significant difference in scoring by 40%. 
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Description: 
 The confidence level is estimated at 95% with a z value of 1.96 
 The confidence interval or margin of error is estimated at +/-12 
 Assuming that the sample will have the specified attribute p% =40 and 
q%=60 
n = p% x q% x [z/e%]² 
n= 40 x 60 x [1.96/12]² 
n= 64.02 
Therefore 64 is the minimum sample size required for the study 
In our study we have taken 75 as the sample size 
 n=25 in Group Gabapentin 
 n=25 in Group Clonidine 
 n=25 in Group Placebo 
MATERIALS 
Monitors- ECG, NIBP, SPO2, EtCo2. 
Drugs: Injection Midazolam, Injection Glycopyrrolate, Inj Fentanyl, 
Inj.Thiopentone Sodium, Inj. atracurium, Inj. Neostigmine, sevoflurane, 
emergency drugs, Normal Saline and Ringer Lactate.  
Airway devices : Mactintosh Laryngoscope, Guedel’s Oral Airway, Gum elastic 
bougie. 
Boyles anaesthesia machine  
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Patients satisfying inclusion criteria were randomly allocated by closed 
envelope method into 3 groups: Group A (Gabapentin), Group B (Clonidine), Group 
C (Placebo). Patients were examined the evening before surgery. They were described 
about the study methods, the visual analogue scale chart and along with information 
sheet. All were orally premedicated with alprazolam 0.5mg at 9.00 pm, the day before 
surgery. 
In the preoperative room, A good intravenous access was secured and baseline 
parameters were noted which includes heart rate (HR), systolic blood pressure(SBP), 
Diastolic blood pressure(DBP), Mean arterial pressure(MAP) and pulse-oximetry 
(SPO2). Patients in group A received Tab Gabapentin 900 mg orally , Group B 
patients will received Tab. Clonidine 0.2mg and Group C patients will received Tab. 
Vitamin C with sips of water 90 minutes prior to induction. Vital parameters were 
recorded 3 minutes before induction. After premedication with Inj.Glycopyrrolate 0.2 
mg IV, Inj.Midazolam 1mg IV, Inj.Fentanyl 2 mcg/ kg IV was given and 
preoxygenation done. Anaesthesia was induced with Inj.Thiopentone sodium 5 mg/ 
kg IV or dose adequate to abolish eye lash reflex, and was followed by a muscle 
relaxant Inj. Atracurium 0.5 mg/ kg IV to facilitate laryngoscopy and intubation. 
Patients were ventilated by mask for atleast 3 minutes using 100% oxygen with 
sevoflurane 1%. Laryngoscopy was performed with a Macintosh laryngoscope and 
trachea was intubated with appropriate sized endotracheal tube by a trained 
anaesthesiologist. The period of laryngoscopy and intubation was less than 15 seconds 
for all patients. Heart rate, systolic blood pressure, diastolic blood pressure, mean 
arterial pressure, pulse-oximetry was monitored and recorded at the time of intubation 
and at 1,3,5,10 minutes after intubation. Maintenance of anaesthesia was carried out 
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using nitrous oxide and oxygen in the ratio of 2:1, sevoflurane 1-2% using controlled 
ventilation.  
Patient was observed for complications like hypotension, hypertension, 
arrhythmias, hypoxemia, and bronchospasm and treated as required. Hypotension is 
defined as fall in SBP/DBP by 30% from baseline and was treated with a bolus of 
intravenous fluid or Inj. Ephedrine 3mg. Bradycardia defined as decrease in heart rate 
to less than 60 min and it was managed with Inj. Atropine 0.6 mg iv and Tachycardia 
is defined as heart rate more than 100/min. Hypertension is when systolic blood 
pressure is more than 30% from baseline. This response was treated by increasing the 
concentration of inhalational anaesthetic agent Sevoflurane and supplemental bolus of 
fentanyl 0.5 mcg/kg. 
At the end of the surgery, residual neuromuscular blockade was reversed with 
Inj. Neostigmine 0.05 mg/kg and Inj. Glycopyrrolate 0.01 mg/kg intravenously. 
Immediate post-extubation, vital parameters, sedation score, anxiety scores were 
recorded. Patient was shifted to PACU and was monitored for vital parameters. VAS 
score and vital parameters were assessed for 1, 2, 4, 6, 8 hours postoperatively. 
Patients were given Inj. Fentanyl 0.5mcg/kg intravenously when the VAS 
score was >3, which was repeated until the pain subsided. Total analgesic requirement 
in postoperative period was recorded. VAS scoring, Ramsay Sedation 
Scoring,Anxiety Scoring and side effects like nausea, vomiting and dizziness were 
recorded. 
RAMSEY SEDATION SCORE: 
1. Anxious, agitated, or restless 
2. Cooperative, oriented and tranquil 
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3. Responds to command 
4. Asleep but has a brisk risk to light glabellar tap or loud auditory stimulus 
5. Asleep but has a sluggish response to light glabellar tap or loud auditory 
stimulus 
6. Asleep, no response 
ANXIETY SCORE 33 
0 - patient quiet and comfortable 
1 - patient uneasy 
2 - patient worried or anxious 
3 - patient very worried or very upset 
4 - patient frightened or terrified. 
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STATISTICAL METHODS 
Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. These included the mean and standard deviation (SD) for 
quantitative variables, and category frequency counts for qualitative variables. Next, 
inferential statistical analysis was undertaken. Continuous variables were analysed 
with the unpaired t-test and categorical variables were analysed with the Chi-Square 
Test with Yates correction. Alpha for significance for all inferences was set at P<0.05. 
All tests of Hypotheses, wherever applicable, were two-tailed. The data was analysed 
using SPSS version 16 and Microsoft Excel 2007. 
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Age  
 
 
 
Age 
Distribution 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
≤ 30 years 2 8.00 3 12.00 5 20.00 
31-40 years 8 32.00 10 40.00 7 28.00 
41-50 years 11 44.00 4 16.00 9 36.00 
51-60 years 4 16.00 8 32.00 4 16.00 
Total 25 100 25 100 25 100 
 
Age Distribution Group Gabapentin Group Clonidine Group Placebo 
N 25 25 25 
Mean 44.28 42.44 40.56 
SD 9.68 11.49 10.29 
P value Unpaired t Test 
Group Gabapentin vs Group Clonidine 0.5433 
Group Gabapentin vs Group Placebo 0.1943 
Group Clonidine vs Group Placebo 0.5451 
 
Majority of the group Gabapentin patients belonged to the 41-50 years age 
class interval (n=11, 44%) with a mean age of 44.28 years. In the group Clonidine 
patients, majority belonged to the 31-40 years age class interval (n=10, 40%) with a 
mean age of 42.44 years. Similarly in the group Placebo patients, majority belonged 
to the 41-50 years age class interval (n=9, 36%) with a mean age of 42.44 years. The 
association between the intervention groups and age distribution is considered to be 
not statistically significant since p > 0.05 as per 2 tail unpaired t test.  
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Gender  
 
 
 
Gender 
Distribution 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
Male 8 32.00 9 36.00 8 32.00 
Female 17 68.00 16 64.00 17 68.00 
Total 25 100 25 100 25 100 
P value Chi Squared Test 
Group Gabapentin vs Group 
Clonidine 0.7653 
Group Gabapentin vs Group 
Placebo >0.9999 
Group Clonidine vs Group 
Placebo 0.7653 
 
Majority of the group Gabapentin patients belonged to female gender (n=17, 
68%). In the group Clonidine patients, majority belonged to female gender (n=16, 
64%). Similarly in the group Placebo patients, majority belonged to female gender 
(n=17, 68%). The association between the intervention groups and gender distribution 
is considered to be not statistically significant since p > 0.05 as per chi squared test. 
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Weight  
 
 
Weight 
Distribution 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
≤ 50 kgs 2 8.00 4 16.00 2 8.00 
51-60 kgs 14 56.00 10 
40.0
0 16 
64.0
0 
61-70 kgs 8 32.00 9 
36.0
0 6 
24.0
0 
71-80 kgs 1 4.00 2 8.00 1 4.00 
Total 25 100 25 100 25 100 
 
Weight Distribution Group Gabapentin Group Clonidine Group Placebo 
N 25 25 25 
Mean 59.00 59.76 57.20 
SD 6.95 7.47 5.71 
P value Unpaired t Test 
Group Gabapentin vs Group Clonidine 0.7112 
Group Gabapentin vs Group Placebo 0.3220 
Group Clonidine vs Group Placebo 0.1803 
 
Majority of the group Gabapentin patients belonged to the 51-60 kgs weight 
class interval (n=14, 56%) with a mean weight of 59.00 kgs. In the group Clonidine 
patients, majority belonged to the 51-60 kgs weight class interval (n=10, 40%) with a 
mean weight of 59.76 kgs. Similarly in the group Placebo patients, majority belonged 
to the 51-60 kgs weight class interval (n=16, 64%) with a mean weight of 57.20 kgs. 
The association between the intervention groups and weight distribution is considered 
to be not statistically significant since p > 0.05 as per 2 tail unpaired t test. 
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Height  
 
 
Height 
Distribution 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
≤ 150 cms 2 8.00 0 0.00 1 4.00 
151-160 cms 15 60.00 14 56.00 17 68.00 
161-170 cms 3 12.00 7 28.00 3 12.00 
171-180 cms 5 20.00 4 16.00 4 16.00 
Total 25 100 25 100 25 100 
 
Height Distribution Group Gabapentin Group Clonidine Group Placebo 
N 25 25 25 
Mean 159.20 160.36 160.16 
SD 8.51 7.42 8.03 
P value Unpaired t Test 
Group Gabapentin vs Group Clonidine 0.6098 
Group Gabapentin vs Group Placebo 0.6835 
Group Clonidine vs Group Placebo 0.9275 
 
Majority of the group Gabapentin patients belonged to the 151-160 cms height 
class interval (n=15, 60%) with a mean height of 159.20 cms. In the group Clonidine 
patients, majority belonged to the 151-160 cms height class interval (n=14, 56%) with 
a mean height of 160.36 cms. Similarly in the group Placebo patients, majority 
belonged to the 151-160 cms height class interval (n=17, 68%) with a mean height of 
160.16 cms. The association between the intervention groups and height distribution 
is considered to be not statistically significant since p > 0.05 as per 2 tail unpaired t 
test.  
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BMI 
 
 
BMI 
Distribution 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
Underweight  
(≤ 18.49) 0 0.00 0 0.00 0 0.00 
Normal  
(18.50 to24.99) 25 100.00 22 88.00 24 96.00 
Overweight  
(25 to 29.99) 0 0.00 3 12.00 1 4.00 
Obese 0 0.00 0 0.00 0 0.00 
Total 25 100 25 100 25 100 
 
BMI Distribution Group Gabapentin Group Clonidine Group Placebo 
N 25 25 25 
Mean 23.17 23.18 22.39 
SD 1.21 1.88 1.60 
P value Unpaired t Test 
Group Gabapentin vs Group Clonidine 0.9794 
Group Gabapentin vs Group Placebo 0.0563 
Group Clonidine vs Group Placebo 0.1128 
 
Majority of the group Gabapentin patients belonged to the Normal BMI class 
interval (n=25, 100%) with a mean BMI of 23.17. In the group Clonidine patients, 
majority belonged to the Normal BMI class interval (n=22, 88%) with a mean BMI of 
23.16. Similarly in the group Placebo patients, majority belonged to the Normal BMI 
class interval (n=24, 96%) with a mean BMI of 22.39. The association between the 
intervention groups and BMI distribution is considered to be not statistically 
significant since p > 0.05 as per 2 tail unpaired t test.  
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ASA 
 
 
ASA Physical 
Status 
Classification 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
ASA 1 15 60.00 14 56.00 16 64.00 
ASA 2 10 40.00 11 44.00 9 36.00 
Total 25 100 25 100 25 100 
P value Chi Squared Test 
Group Gabapentin vs Group 
Clonidine 0.7745 
Group Gabapentin vs Group 
Placebo 0.7708 
Group Clonidine vs Group 
Placebo 0.5637 
 
Majority of the group Gabapentin patients belonged to ASA Physical Status 
Classification 1 (n=15, 60%). In the group Clonidine patients, majority belonged to 
ASA Physical Status Classification 1 (n=14, 56%). Similarly in the group Placebo 
patients, majority belonged to ASA Physical Status Classification 1 (n=16, 64%). The 
association between the intervention groups and ASA Physical Status Classificationis 
considered to be not statistically significant since p > 0.05 as per chi squared test. 
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Heart Rate 
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Heart Rate Distribution Baseline 
3 Minutes 
Prior to 
Induction 
During 
Induction 
During 
Intubation 
1 Minute 
after 
Intubation 
3 Minutes 
after 
Intubation 
5 Minutes 
after 
Intubation 
10 Minutes 
after 
Intubation 
Group Gabapentin 
N 25 25 25 25 25 25 25 25 
Mean 75.28 73.64 74.52 86.28 97.48 96.16 90.88 85.64 
SD 9.13 4.20 4.85 8.81 11.11 11.08 10.06 8.04 
Group Clonidine 
N 25 25 25 25 25 25 25 25 
Mean 77.44 70.40 69.68 72.52 73.28 72.12 70.48 69.80 
SD 8.60 5.91 4.69 7.19 5.26 4.56 5.82 5.18 
Group Placebo 
N 25 25 25 25 25 25 25 25 
Mean 77.88 77.64 76.64 85.80 97.52 105.24 103.80 97.84 
SD 9.72 12.76 11.14 6.84 7.60 7.24 8.44 9.59 
P value Unpaired  
t Test 
Group Gabapentin 
vs Group Clonidine 0.3936 0.0269 0.0010 0.0000 0.0000 0.0000 0.0000 0.0000 
Group Gabapentin 
vs Group Placebo 0.3345 0.0472 0.0393 0.0006 0.0182 0.0014 0.0000 0.0000 
Group Clonidine vs 
Group Placebo 0.8661 0.0141 0.0073 0.0000 0.0000 0.0000 0.0000 0.0000 
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Heart Rate Distribution 
Post-op  
 0 hr 
Post-op  
1st hr 
Post-op  
2nd hr 
Post-op  
4th hr 
Post-op  
 6thhr 
Post-op  
 8th hr 
Group Gabapentin 
N 25 25 25 25 25 25 
Mean 88.76 76.76 75.84 75.52 75.92 77.52 
SD 6.49 5.86 5.34 4.47 4.83 4.00 
Group Clonidine 
N 25 25 25 25 25 25 
Mean 75.08 71.84 70.60 70.36 71.12 72.84 
SD 6.40 6.05 7.39 6.14 5.34 5.25 
Group Placebo 
N 25 25 25 25 25 25 
Mean 102.36 82.76 80.16 80.76 80.36 79.84 
SD 9.08 8.56 7.96 6.13 5.98 5.44 
P value Unpaired t Test 
Group Gabapentin vs Group Clonidine 0.0000 0.0053 0.0062 0.0015 0.0017 0.0009 
Group Gabapentin vs Group Placebo 0.0000 0.0060 0.0296 0.0012 0.0059 0.0930 
Group Clonidine vs Group Placebo 0.0000 0.0000 0.0001 0.0000 0.0000 0.0000 
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By conventional criteria the association between the intervention groups and heart 
rate status among study subjects is considered to be statistically significant since p < 
0.05.  
 
Results  
In patients belonging to group Gabapentin, the mean heart rate is 82.69 bpm. In 
group Clonidine the mean heart rate is 71.55 bpm. Similarly in group placebo the mean 
heart rate is 88.52 bpm. 
 
The increased the mean heart rate measurement in group Gabapentin compared to 
the group Clonidine is statistically significant as the p value is 0.0033 as per unpaired t- 
test indicating a difference among study groups.The mean heart rate measurement was 
meaningfully more in group Gabapentin compared to group Clonidine by 1.16 times with 
a mean difference of 11.14 bpm. 
 
The decreased the mean heart rate measurement in group Gabapentin compared to 
the group placebo is statistically significant as the p value is 0.0197 as per unpaired t- test 
indicating a difference among study groups.The mean heart rate measurement was 
meaningfully less in group Gabapentin compared to group placebo by 7% with a mean 
difference of 5.83 bpm. 
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The decreased the mean heart rate measurement in group Clonidine compared to 
the group placebo is statistically significant as the p value is 0.0017 as per unpaired t- test 
indicating a difference among study groups.The mean heart rate measurement was 
meaningfully less in group Clonidine compared to group placebo by 19% with a mean 
difference of 16.97 bpm.  
 
This difference is true and significant and has not occurred by chance. 
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Systolic blood  
pressure Distribution Baseline 
3 Minutes 
Prior to 
Induction 
During 
Induction 
During 
Intubation 
1 Minute 
after 
Intubation 
3 Minutes 
after 
Intubation 
5 Minutes 
after 
Intubation 
10 
Minutes 
after 
Intubation 
Group Gabapentin 
N 25 25 25 25 25 25 25 25 
Mean 123.60 122.72 120.64 125.36 125.20 124.40 121.28 121.24 
SD 10.89 7.62 7.61 8.72 5.70 7.56 4.94 4.40 
Group Clonidine 
N 25 25 25 25 25 25 25 25 
Mean 124.72 117.00 116.32 117.04 116.88 114.68 114.56 112.60 
SD 10.68 7.83 6.23 7.95 6.32 6.57 6.57 5.01 
Group Placebo 
N 25 25 25 25 25 25 25 25 
Mean 124.72 121.24 162.08 134.40 142.04 146.36 140.88 134.84 
SD 10.33 9.66 10.21 6.96 8.00 6.22 5.81 5.75 
P value Unpaired 
 t Test 
Group Gabapentin vs 
Group Clonidine 
0.7151 0.0090 0.0399 0.0009 0.0000 0.0000 0.0002 0.0000 
Group Gabapentin vs 
Group Placebo 
0.7108 0.0459 0.0324 0.0002 0.0000 0.0000 0.0000 0.0000 
Group Clonidine vs 
Group Placebo 
1.0000 0.0402 0.0257 0.0000 0.0000 0.0000 0.0000 0.0000 
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Systolic blood pressure Distribution 
Post-op  
 0 hr 
Post-op  
1 hr 
Post-op  
2 hr 
Post-op  
 4 hr 
Post-op  
 6 hr 
Post-op  
8 hr 
Group Gabapentin 
N 25 25 25 25 25 25 
Mean 131.12 119.04 118.36 119.56 122.60 123.40 
SD 7.25 2.95 4.64 4.47 4.45 4.34 
Group Clonidine 
N 25 25 25 25 25 25 
Mean 120.92 113.64 113.00 114.76 116.48 117.80 
SD 5.57 6.84 7.19 6.04 6.25 4.76 
Group Placebo 
N 25 25 25 25 25 25 
Mean 141.28 126.96 126.60 124.56 125.08 126.04 
SD 6.52 5.40 6.08 4.01 6.03 4.63 
P value Unpaired t Test 
Group Gabapentin 
vs Group 
Clonidine 
0.0000 0.0010 0.0032 0.0026 0.0003 0.0001 
Group Gabapentin 
vs Group Placebo 
0.0000 0.0000 0.0000 0.0001 0.1053 0.0430 
Group Clonidine 
vs Group Placebo 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
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By conventional criteria the association between the intervention groups and 
systolic blood pressure status among study subjects is considered to be statistically 
significant since p < 0.05.  
 
Results  
In patients belonging to group Gabapentin, the mean systolic blood pressure is 
122.69 mm Hg. In group Clonidine the mean systolic blood pressure is 115.82 mm Hg. 
Similarly in group placebo the mean systolic blood pressure is 134.80 mm Hg. 
 
The increased the mean systolic blood pressure measurement in group Gabapentin 
compared to the group Clonidine is statistically significant as the p value is 0.0044 as per 
unpaired t- test indicating a true difference among study groups. The mean systolic 
blood pressure measurement was meaningfully more in group Gabapentin compared to 
group Clonidine by 1.06 times with a mean difference of 6.86 mm Hg.  
 
The decreased the mean systolic blood pressure measurement in group 
Gabapentin compared to the group placebo is statistically significant as the p value is 
0.0382 as per unpaired t- test indicating a true difference among study groups. The mean 
systolic blood pressure measurement was meaningfully less in group Gabapentin 
compared to group placebo by 9% with a mean difference of 12.11 mm Hg.  
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The decreased the mean systolic blood pressure measurement in group Clonidine 
compared to the group placebo is statistically significant as the p value is 0.0274 as per 
unpaired t- test indicating a true difference among study groups. The mean systolic blood 
pressure measurement was meaningfully less in group Clonidine compared to group 
placebo by 14% with a mean difference of 18.98 mm Hg.  
This difference is true and significant and has not occurred by chance. 
 63 
DBP 
 
 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
Baseline 3 Minutes Prior 
to Induction
During 
Induction
During 
Intubation
1 Minute after 
Intubation
3 Minutes after 
Intubation
5 Minutes after 
Intubation
10 Minutes 
after Intubation
M
ea
n 
D
B
P 
(m
m
 H
g)
Diastolic Blood pressure Distribution
Group Gabapentin Group Clonidine Group Placebo
 64 
Diastolic blood pressure 
Distribution Baseline 
3 Minutes 
Prior to 
Induction 
During 
Induction 
During 
Intubation 
1 Minute 
after 
Intubation 
3 Minutes 
after 
Intubation 
5 Minutes 
after 
Intubation 
10 Minutes 
after 
Intubation 
Group 
Gabapentin 
N 25 25 25 25 25 25 25 25 
Mean 79.20 79.68 75.56 80.40 81.80 78.68 77.16 77.08 
SD 8.07 5.11 6.33 6.89 4.48 4.99 4.17 5.14 
Group 
Clonidine 
N 25 25 25 25 25 25 25 25 
Mean 79.12 72.36 73.16 73.00 72.68 72.44 72.24 70.16 
SD 7.76 4.32 4.26 5.14 4.42 5.02 4.80 4.55 
Group 
Placebo 
N 25 25 25 25 25 25 25 25 
Mean 78.12 76.76 79.20 85.20 91.28 93.84 87.84 84.60 
SD 7.89 7.08 6.14 5.31 4.81 5.21 5.09 3.93 
P value 
Unpaired t 
Test 
Group Gabapentin  
vs 
Group Clonidine 
0.9716 0.0000 0.0429 0.0001 0.0000 0.0001 0.0003 0.0000 
Group Gabapentin  
vs 
Group Placebo 
0.6345 0.0119 0.0330 0.0083 0.0000 0.0000 0.0000 0.0000 
Group Clonidine  
vs 
Group Placebo 
0.6536 0.0140 0.0002 0.0000 0.0000 0.0000 0.0000 0.0000 
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Diastolic blood pressure Distribution Post-op  0 hr 
Post-op 
1st hr 
Post-op  
2nd hr 
Post-op 
4th hr 
Post-op 
 6th r 
Post-op 
8th hr 
Group Gabapentin 
N 25 25 25 25 25 25 
Mean 83.48 74.16 72.48 75.32 76.00 78.84 
SD 6.29 4.62 3.47 4.32 4.11 3.95 
Group Clonidine 
N 25 25 25 25 25 25 
Mean 73.60 68.48 69.44 70.64 73.68 75.12 
SD 5.34 4.98 5.05 4.25 5.60 3.78 
Group Placebo 
N 25 25 25 25 25 25 
Mean 91.28 79.76 79.28 77.76 79.72 79.28 
SD 6.24 5.36 4.77 5.24 4.01 3.66 
P value Unpaired t Test 
Group Gabapentin vs 
Group Clonidine 
0.0000 0.0001 0.0171 0.0007 0.1019 0.0007 
Group Gabapentin vs 
Group Placebo 
0.0001 0.0003 0.0000 0.0288 0.0022 0.0048 
Group Clonidine vs 
Group Placebo 
0.0000 0.0000 0.0000 0.0000 0.0001 0.0001 
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By conventional criteria the association between the intervention groups and 
diastolic blood pressure status among study subjects is considered to be statistically 
significant since p < 0.05.  
 
Results  
In patients belonging to group Gabapentin, the mean diastolic blood pressure is 
77.74 mm Hg. In group Clonidine the mean diastolic blood pressure is 72.08 mm Hg. 
Similarly in group placebo the mean diastolic blood pressure is 83.52 mm Hg. 
 
The increased the mean diastolic blood pressure measurement in group 
Gabapentin compared to the group Clonidine is statistically significant as the p value is 
0.0203 as per unpaired t-test indicating a true difference among study groups.The mean 
diastolic blood pressure measurement was meaningfully more in group Gabapentin 
compared to group Clonidine by 1.08 times with a mean difference of 5.66 mm Hg. 
 
The decreased the mean diastolic blood pressure measurement in group 
Gabapentin compared to the group placebo is statistically significant as the p value is 
0.0415 as per unpaired t- test indicating a true difference among study groups. The 
mean diastolic blood pressure measurement was meaningfully less in group Gabapentin 
compared to group placebo by 7% with a mean difference of 5.78 mm Hg.  
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The decreased the mean diastolic blood pressure measurement in group Clonidine 
compared to the group placebo is statistically significant as the p value is 0.0011 as per 
unpaired t-test indicating a true difference among study groups.The mean diastolic blood 
pressure measurement was meaningfully less in group Clonidine compared to group 
placebo by 14% with a mean difference of 11.45 mm Hg.  
 
This difference is true and significant and has not occurred by chance. 
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Mean Arterial Pressure Distribution Baseline 
3 Minutes 
Prior to 
Induction 
During 
Induction 
During 
Intubation 
1 Minute 
after 
Intubation 
3 Minutes 
after 
Intubation 
5 Minutes 
after 
Intubation 
10 
Minutes 
after 
Intubation 
 
Group 
Gabapentin 
N 25 25 25 25 25 25 25 25 
Mean 94.00 94.03 90.59 91.73 96.27 93.92 91.87 91.80 
SD 8.62 5.71 6.73 6.02 4.31 5.32 3.64 4.34 
Group 
Clonidine 
N 25 24 25 25 25 25 25 25 
Mean 94.32 87.18 87.55 86.26 87.41 86.52 86.35 84.31 
SD 8.23 5.67 4.51 7.83 4.46 5.21 4.95 4.32 
Group 
Placebo 
N 25 25 25 25 25 25 25 25 
Mean 93.65 91.59 106.83 101.75 108.20 111.35 105.52 101.35 
SD 7.72 4.98 66.81 44.11 4.81 5.04 4.88 3.87 
P value 
Unpaired 
t Test 
Group Gabapentin  
vs 
Group Clonidine 
0.8938 0.0001 0.0677 0.0055 0.0000 0.0000 0.0001 0.0000 
Group Gabapentin  
vs 
Group Placebo 
0.8815 0.0142 0.2381 0.0257 0.0000 0.0000 0.0000 0.0000 
Group Clonidine  
vs 
Group Placebo 
0.7690 0.0039 0.1628 0.0283 0.0000 0.0000 0.0000 0.0000 
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Mean Arterial Pressure Distribution Post-op  0 hr 
Post-op  
1sthr 
Post-op  
2nd hr 
Post-op  
 4th hr 
Post-op  
 6 hr 
Post-op  
 8th hr 
Group Gabapentin 
N 25 25 25 25 25 25 
Mean 99.36 89.12 87.77 90.07 91.53 93.69 
SD 6.26 3.70 3.51 3.62 3.89 3.52 
Group Clonidine 
N 25 25 25 25 25 25 
Mean 89.37 83.53 83.96 85.35 87.95 89.35 
SD 4.52 5.03 5.10 4.62 5.00 3.36 
Group Placebo 
N 25 25 25 25 25 25 
Mean 107.95 95.49 95.05 93.36 94.84 94.87 
SD 6.08 4.93 4.65 4.20 4.21 3.49 
P value Unpaired t Test 
Group Gabapentin  
vs 
Group Clonidine 
0.0000 0.0001 0.0036 0.0002 0.0069 0.0000 
Group Gabapentin  
vs 
Group Placebo 
0.0000 0.0000 0.0000 0.0046 0.0059 0.2431 
Group Clonidine  
vs 
Group Placebo 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
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By conventional criteria the association between the intervention groups and 
arterial pressure status among study subjects is considered to be statistically significant 
since p < 0.05.  
 
Results  
In patients belonging to group Gabapentin, the mean arterial pressure is 92.44 mm 
Hg. In group Clonidine the mean arterial pressure is 86.54 mm Hg. Similarly in group 
placebo the mean arterial pressure is 100.63 mm Hg. 
 
The increased the mean arterial pressure measurement in group Gabapentin 
compared to the group Clonidine is statistically significant as the p value is 0.0065 as per 
unpaired t-test indicating a true difference among study groups.The mean arterial 
pressure measurement was meaningfully more in group Gabapentin compared to group 
Clonidine by 1.07 times with a mean difference of 5.90 mm Hg.  
 
The decreased the mean arterial pressure measurement in group Gabapentin 
compared to the group placebo is statistically significant as the p value is 0.0478 as per 
unpaired t-test indicating a true difference among study groups.The mean arterial 
pressure measurement was meaningfully less in group Gabapentin compared to group 
placebo by 8% with a mean difference of 8.18 mm Hg.  
 
 74 
The decreased the mean arterial pressure measurement in group Clonidine 
compared to the group placebo is statistically significant as the p value is 0.0204 as per 
unpaired t-test indicating a true difference among study groups.The mean arterial 
pressure measurement was meaningfully less in group Clonidine compared to group 
placebo by 14% with a mean difference of 14.08 mm Hg.  
 
This difference is true and significant and has not occurred by chance. 
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Visual Analog Score Pre-op Post-op  0 hr 
Post-op  
1sthr 
Post-op 
2nd hr 
Post-op 
 4th hr 
Post-op 
 6th hr 
Post-op 
 8th hr 
Group 
Gabapentin 
N 25 25 25 25 25 25 25 
Mean 0.40 2.08 1.96 2.76 2.24 1.92 1.80 
SD 0.50 0.57 0.54 0.56 0.60 0.40 0.50 
Group 
Clonidine 
N 25 25 25 25 25 25 25 
Mean 0.72 3.80 3.56 3.04 2.80 2.60 2.48 
SD 0.46 0.65 0.58 0.73 0.82 0.65 0.59 
Group 
Placebo 
N 25 25 25 25 25 25 25 
Mean 0.84 5.76 4.16 4.16 4.00 3.84 3.28 
SD 0.55 1.20 1.11 1.07 0.76 0.62 0.61 
P value 
Unpaired t 
Test 
Group 
Gabapentin 
vs Group 
Clonidine 
0.0225 0.0000 0.0000 0.0461 0.0082 0.0001 0.0001 
Group 
Gabapentin 
vs Group 
Placebo 
0.0049 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
Group 
Clonidine vs 
Group 
Placebo 
0.4081 0.0000 0.0217 0.0001 0.0000 0.0000 0.0000 
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By conventional criteria the association between the intervention groups and 
visual analog score among study subjects is considered to be statistically significant since 
p < 0.05.  
 
Results  
Inpatients belonging to group Gabapentin, the mean VAS is 1.78 points. In group 
Clonidine the mean VAS is 2.00 points. Similarly in group placebo the mean VAS is 2.70 
points. 
 
The decreased the mean VAS measurement in group Gabapentin compared to the 
group Clonidine is statistically significant as the p value is 0.0059 as per unpaired t-test 
indicating a true difference among study groups. The mean VAS measurement was 
meaningfully less in group Gabapentin compared to group Clonidine by 11% with a 
mean difference of 0.22 points.  
 
The decreased the mean VAS measurement in group Gabapentin compared to the 
group placebo is statistically significant as the p value is 0.0196 as per unpaired t-test 
indicating a true difference among study groups. The mean VAS measurement was 
meaningfully less in group Gabapentin compared to group placebo by 34% with a mean 
difference of 0.91 points. 
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The decreased the mean VAS measurement in group Clonidine compared to the 
group placebo is statistically significant as the p value is 0.0254 as per unpaired t-test 
indicating a true difference among study groups. The mean VAS measurement was 
meaningfully less in group Clonidine compared to group placebo by 26% with a mean 
difference of 0.70 points.  
 
This difference is true and significant and has not occurred by chance. 
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Anxiety Score 
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Anxiety Score Pre-op Post-op  0 hr 
Post- op 
1sthr 
Post-op 
2nd hr 
Post-op 
4th hr 
Post-op 
6th hr 
Post-op 
8th hr 
Group 
Gabapentin 
N 25 25 25 25 25 25 25 
Mean 0.36 0.40 0.36 0.64 0.96 1.20 1.60 
SD 0.49 0.50 0.49 0.49 0.54 0.41 0.58 
Group 
Clonidine 
N 25 25 25 25 25 25 25 
Mean 0.36 0.12 0.40 0.44 0.92 1.28 1.32 
SD 0.49 0.33 0.50 0.51 0.28 0.46 0.48 
Group 
Placebo 
N 25 25 25 25 25 25 25 
Mean 1.68 2.12 1.64 1.60 1.56 1.72 2.04 
SD 0.80 0.60 0.50 0.49 0.74 0.58 0.35 
P value 
Unpaired t 
Test 
Group 
Gabapentin 
vs Group 
Clonidine 
1.0000 0.0245 0.0163 0.0324 0.0431 0.0177 0.0677 
Group 
Gabapentin 
vs Group 
Placebo 
0.0000 0.0000 0.0000 0.0000 0.0004 0.0038 0.0023 
Group 
Clonidine 
vs Group 
Placebo 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0153 0.0000 
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By conventional criteria the association between the intervention groups and 
Anxiety Score among study subjects is considered to be statistically significant since p < 
0.05.  
Results  
In patients belonging to group Gabapentin, the mean Anxiety Score is 0.73 points. 
In group Clonidine the mean Anxiety Score is 0.68 points. Similarly in group placebo the 
mean Anxiety Score is 1.41 points. 
The increased the mean Anxiety Score measurement in group Gabapentin 
compared to the group Clonidine is statistically significant as the p value is 0.0378 as per 
unpaired t- test indicating a true difference among study groups. The mean Anxiety Score 
measurement was meaningfully more in group Gabapentin compared to group Clonidine 
by 1.08 times with a mean difference of 0.05 points.  
The decreased the mean Anxiety Score measurement in group Gabapentin 
compared to the group placebo is statistically significant as the p value is 0.0082 as per 
unpaired t- test indicating a true difference among study groups. The mean Anxiety Score 
measurement was meaningfully less in group Gabapentin compared to group placebo by 
48% with a mean difference of 0.68 points.  
The decreased the mean Anxiety Score measurement in group Clonidine 
compared to the group placebo is statistically significant as the p value is 0.0358 as per 
unpaired t- test indicating a true difference among study groups. The mean Anxiety Score 
measurement was meaningfully less in group Clonidine compared to group placebo by 
52% with a mean difference of 0.73 points.  
This difference is true and significant and has not occurred by chance. 
 82 
 
Ramsay Sedation Score 
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Ramsay Sedation Score Pre- operative 
Post –op 
0 hr 
Post –op 
1sthr 
Post –op 
2nd hr 
Post –op 
4th hr 
Post –op 
6th hr 
Post- op 
8th hr 
Group Gabapentin 
N 25 25 25 25 25 25 25 
Mean 1.92 2.84 2.64 2.40 1.88 1.64 1.28 
SD 0.76 0.47 0.49 0.58 0.53 0.57 0.54 
Group Clonidine 
N 25 25 25 25 25 25 25 
Mean 1.28 2.00 1.76 1.68 1.28 1.00 1.00 
SD 0.46 0.58 0.52 0.48 0.46 0.00 0.00 
Group Placebo 
N 25 25 25 25 25 25 25 
Mean 1.00 1.04 1.12 1.16 1.00 1.00 1.00 
SD 0.00 0.20 0.33 0.37 0.00 0.00 0.00 
P value Unpaired t Test 
Group Gabapentin 
vs 
Group Clonidine 
0.0009 0.0000 0.0000 0.0000 0.0001 0.0000 0.0162 
Group Gabapentin 
vs 
Group Placebo 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0162 
Group Clonidine 
vs 
Group Placebo 
0.0054 0.0000 0.0000 0.0001 0.0054 >0.9999 >0.9999 
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By conventional criteria the association between the intervention groups and 
Ramsay sedation score among study subjects is considered to be statistically 
significant since p < 0.05.  
Results  
In patients belonging to group Gabapentin, the mean Ramsay sedation score is 
1.89 points. In group Clonidine the mean Ramsay sedation score is 1.31 points. 
Similarly in group placebo the mean Ramsay sedation score is 1.26 points. 
The increased the mean Ramsay sedation score measurement in group 
Gabapentin compared to the group Clonidine is statistically significant as the p value 
is 0.0085 as per unpaired t-test indicating a true difference among study groups. The 
mean Ramsay sedation score measurement was meaningfully more in group 
Gabapentin compared to group Clonidine by 1.45 times with a mean difference of 
0.68 points. 
The increased the mean Ramsay sedation score measurement in group 
Gabapentin compared to the group placebo is statistically significant as the p value is 
0.0396 as per unpaired t-test indicating a true difference among study groups. The 
mean Ramsay sedation score measurement was meaningfully more in group 
Gabapentin compared to group placebo by 1.51 times with a mean difference of 0.64 
points. 
The increased the mean Ramsay sedation score measurement in group 
Clonidine compared to the group placebo is statistically significant as the p value is 
0.0162 as per unpaired t- test indicating a true difference among study groups.  
The mean Ramsay sedation score measurement was meaningfully more in 
group Clonidine compared to group placebo by 1.04 times with a mean difference of 
0.05 points. 
This difference is true and significant and has not occurred by chance. 
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Fentanyl Dosage 
 
 
 
 
Fentanyl 
Dosage 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
≤ 50 mcg 25 100.00 1 4.00 0 0.00 
51-100 mcg 0 0.00 19 76.00 4 16.00 
101-150 mcg 0 0.00 5 20.00 10 40.00 
151-200 mcg 0 0.00 0 0.00 9 36.00 
> 200 mcg 0 0.00 0 0.00 2 8.00 
Total 25 100.00 25 100.00 25 100.00 
 
 
Fentanyl Dosage Group Gabapentin Group Clonidine Group Placebo 
N 25 25 25 
Mean 26.80 89.20 148.40 
SD 11.80 19.56 40.38 
P value Unpaired t Test 
Group Gabapentin vs Group Clonidine 0.0000 
Group Gabapentin vs Group Placebo 0.0000 
Group Clonidine vs Group Placebo 0.0000 
 
By conventional criteria the association between the intervention groups and 
Fentanyl dosage among study subjects is considered to be statistically significant 
since p < 0.05.   
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Results  
In patients belonging to group Gabapentin, the mean Fentanyl dosage is 26.80 
mcg. In group Clonidine the mean Fentanyl dosage is 89.20 mcg. Similarly in group 
placebo the mean Fentanyl dosage is 148.40 mcg. 
The decreased the mean Fentanyl dosage measurement in group Gabapentin 
compared to the group Clonidine is statistically significant as the p value is 0.0000 as 
per unpaired t-test indicating a true difference among study groups. The mean 
Fentanyl dosage measurement was meaningfully less in group Gabapentin compared 
to group Clonidine by 70% with a mean difference of 62.40 mcg. 
The decreased the mean Fentanyl dosage measurement in group Gabapentin 
compared to the group placebo is statistically significant as the p value is 0.0000 as 
per unpaired t-test indicating a true difference among study groups. The mean 
Fentanyl dosage measurement was meaningfully less in group Gabapentin compared 
to group placebo by 82% with a mean difference of 121.60 mcg. 
The decreased the mean Fentanyl dosage measurement in group Clonidine 
compared to the group placebo is statistically significant as the p value is 0.0000 as 
per unpaired t- test indicating a true difference among study groups. The mean 
Fentanyl dosage measurement was meaningfully more in group Clonidine compared 
to group placebo by 40% with a mean difference of 59.20 mcg.  
This difference is true and significant and has not occurred by chance. 
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Complications  
 
 
 
Complicat
ions 
Group 
Gabapentin % 
Group 
Clonidine % 
Group 
Placebo % 
Nausea 6 24.00 3 12.00 2 8.00 
Vomiting 1 4.00 1 4.00 1 4.00 
Drowsines
s 11 44.00 3 12.00 0 0.00 
Nil 7 28.00 18 72.00 22 88.00 
Total 25 100 25 100 25 100 
P value Fishers Exact Test 
Group Gabapentin Vs Group 
Clonidine 0.3858 
Group Gabapentin Vs Group 
Placebo 0.4696 
Group Clonidine Vs Group 
Placebo 0.3430 
 
Majority of the group Gabapentin patients had drowsiness as complication 
(n=11, 44%). In the group Clonidine patients, majority had no complication (n=18, 
72%). Similarly in the group Placebo patients, majority had no complication (n=22, 
88%). The association between the intervention groups and complications status is 
considered to be not statistically significant since p > 0.05 as per chi squared test. 
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DISSCUSION 
Innumerable anaesthetic techniques have been proposed to attenuate the stress 
response to laryngoscopy and tracheal intubation, with variable grades of success in 
acute post-operative pain relief. The achievement of good postoperative analgesia as a 
bonus to the smooth induction with negligible reflex haemodynamic response in the 
course of laryngoscopy and endotracheal intubation remains an important anaesthetic 
goal.  
This study was done to assess the pre-emptive analgesic effects of two drug 
namely, Gabapentin 900mg and Clonidine 0.2mg. These two drugs when given orally, 
have a role in attenuating hemodynamic stress response to laryngoscopy and tracheal 
intubation and also in decreasing acute postoperative pain relief. 
 Single dose Gabapentin, when used as pre-treatment prevented dose- 
dependent development of hyperalgesia and tactile allodynia. In a study by Welty  
et al57 found that Gabapentin readily crosses the blood brain barrier and its 
concentration in brain is nearly similar to that present in blood. So Gabapentin is at its 
highest concentration in plasma and brain tissue, prevented peripheral and central 
sensitization by decreasing hyperalgesia and allodynia associated with surgical 
manipulation by inhibiting membrane voltage gated calcium channels, which is 
similar to calcium channel blockers37.The mechanism of Gabapentin which decreases 
the hemodynamic response to laryngoscopy and tracheal intubation is unknown.37 
Clonidine is mostly used as an antihypertensive drug and has an analgesic, 
sedative, and anxiolytic properties.32, 33By its central sympatholytic action, it tends to 
attenuate the hemodynamic response to any surgical stimulus and improve overall 
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peri-anaesthetic cardiovascular stability and by central α2 agonist activity, mediates 
postoperative analgesia. 
The doses of these two drugs for pre-emptive analgesia were selected based on 
previous studies. Those studies used oral Gabapentin in the range of 300-1600mg (in 
both single and multiple doses), and oral Clonidine in the range of 0.1-0.3 mg. In this 
study we used 900 mg Gabapentin and 0.2 mg Clonidine orally in line with many 
authors. The drugs were orally administered 90 minutes prior to induction, as the peak 
action of both the drugs are known to be 1-2 hours after oral administration. 
Variation of heart rate changes decreases with increasing age. Young patients 
show more extreme changes. Marked fluctuations in hemodynamic response are often 
seen in geriatric patients. To avoid these above mentioned age related variability, we 
selected an age range of 18-60 years in our study. 
In the present study there were certain changes in all the three groups, 
 Heart rate changes were lower in patients with oral Clonidine as compared to 
the other two groups (However, Gabapentin group swings were less wider 
than the placebo group). 
 Systolic blood pressure, Diastolic blood pressure and the Mean arterial 
pressure changes were lower in patients with oral Clonidine compared to the 
other two groups (However oral Gabapentin swings were less wider than the 
placebo group) 
 VAS scoring were much lower in patients with oral Gabapentin compared to 
the other two groups (Clonidine < placebo group). 
 Anxiety Scores were higher in patients with oral placebo compared to other 
two groups (oral Gabapentin > Clonidine) 
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  Ramsay sedation scores were higher in patients with oral Gabapentin 
compared to other two groups (Clonidine > placebo) 
 The Fentanyl dosage need was considerably lower in patients with oral 
Gabapentin compared to other two groups (Clonidine < placebo) 
When comparing all the 3 groups i.e. Gabapentin, Clonidine and placebo, 
there was reduction in haemodynamic response with Clonidine and Gabapentin. This 
analysis indicates that both Gabapentin and Clonidine have a role in attenuating 
hemodynamic stress response to laryngoscopy and tracheal intubation and help in 
maintaining a steady haemodynamic state all throughout the procedure. However 
there was a tachycardia within acceptable limits with Gabapentin lasting for upto 20-
30 minutes post-intubation. 
Similarly, when comparing all the groups, there is significantly decreased need 
for analgesic requirement in both Gabapentin and Clonidine groups than the placebo 
group. 
Our study also proved the role of oral Gabapentin and oral Clonidine in 
attenuating peri-operative cardiovascular stress responses and decreasing post-
operative analgesic requirements, which were verified by many other studies done 
previously. 
Suresh K Singhal et al 45 showed that oral Clonidine 200 μcg when given 90 
min before induction, provides good attenuation of hemodynamic response to 
laryngoscopy and intubation as compared with oral Gabapentin (900 mg), which also 
fairly obtunded the hypertensive response, but not the tachycardia. In our study also 
we observed similar findings. 
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Indira kumara et al16, have studies the changes in SBP, DBP, MAP and HR 
following laryngoscopy and intubation after administering Gabapentin 900mg 2 hours 
before induction. Significant rise in SBP, DBP, MAP was observed following 
laryngoscopy and tracheal intubation in placebo groups as compared to Gabapentin 
groups. No significant change in heart rate was documented in both groups. 
In a study by Pandey CK ET al 31 fentanyl requirement is decreased in 
patients undergoing lumbar discectomy in Gabapentin group who received 600 mg. 
Similar results were obtained by Turan A et al51 for spinal surgeries. Turan A et al 50 
found a decrease in tramadol consumption in patients who were given Gabapentin for 
abdominal hysterectomy. In other studies by Fassoulaki A et al,7 opioid consumption 
in post-operative period is decreased  
Marashi et al 39, found that after oral administration of 900 mg Gabapentin, 
0.2 mg Clonidine, 2 hours before surgery and when compared to a placebo group 
showed that lowest rates of SBP, DBP, and MAP were seen in Gabapentin group, but 
Clonidine also had similar blunting effects.  
In a study by Elina M. Tiippana et al 6, it was found that one dose of 
Gabapentin orally ranging from 300-1200mg when given preoperatively reduces 
opioid consumption by 20-60%. They also found that dose of Gabapentin used did not 
have any outcome on opioid consumption. In this study postoperative VAS score 
were significantly lesser in Gabapentin group compared to placebo group. 
From the above studies most of the authors have used doses ranging from 600-
900 mg of Gabapentin, in their studies and found to be effective. In our study we used 
900mg Gabapentin and this dose was found to be effective in blunting stress response 
with regard to HR, SBP, DBP, and MAP. 
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Barat YK et al, 2 studied the attenuation of heart rate and blood pressure 
response to laryngoscopy and intubation by Clonidine in 40 healthy patients. Heart 
rate and blood pressures were significantly lower in the Clonidine group immediately 
after intubation (p<0.05) 
Ghignone M et al, 10 studied the effects of oral Clonidine on depths of 
fentanyl anaesthesia and on cardiovascular response to laryngoscopy and intubation in 
24 patients undergoing aorto-coronary bypass surgery and concluded that oral 
Clonidine reduced the fentanyl requirement and prevented the hemodynamic response 
to intubation. 
Matot et al 24, study shows that, in patients undergoing laparoscopic 
procedures under general anaesthesia, premedication with oral Clonidine attenuates 
hemodynamic responses. In our study, premedication with Clonidine 0.2mg 
administrated 90 minutes before surgery significantly reduced HR, SBP, DBP, and 
MAP after endotracheal intubation. 
According to study conducted by Mc Lean et al, 25 use of Gabapentin is 
associated with side effects like nausea, vomiting, dizziness, confusion, headache, 
ataxia and weight gain. In a study by C K Pandey et al 32 in patients undergoing 
laparoscopic cholecystectomy it was found that there was higher incidence of sedation 
in Gabapentin groups of patients. 
In our study also, incidence of sedation, nausea and vomiting were more with 
Gabapentin than other two groups.  
The studies conducted by above authors also used similar dosage of Clonidine 
as we used in our study. With this dose of oral Clonidine 0.2 mg prior to induction, 
we noticed similar effective blunting of stress response during laryngoscopy and 
tracheal intubation and noticed similar effectiveness in post-operative pain relief. 
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SUMMARY 
This is a prospective randomised double blinded, case control study with 
respect to a placebo, to evaluate the pre-emptive analgesic effects of oral Gabapentin 
900mg and oral Clonidine 0.2mg on intubation response and post-operative analgesic 
requirements. 
By giving Gabapentin and Clonidine orally 90 minutes preoperatively, it 
reaches peak concentration in plasma at the onset of surgical stimulus thereby 
inhibiting central and peripheral neuronal sensitization to pain. By inhibiting the 
initiation of noxious input it reduces intubation response and post-operative pain 
intensity and analgesic prerequisites. 
Seventy five patients satisfying the inclusion criteria were randomly divided 
into three groups of twenty five each. Group A received Gabapentin, group B 
received Clonidine, group C received placebo of vitamin C tablet 90 minutes prior to 
induction. Intra-operatively patients were monitored for HR, SBP, DBP, and MAP 
during intubation and post-operatively monitored for sedation, anxiety level, VAS 
score and total analgesic requirement upto 8 hours. The data derived was evaluated. 
Observations of the study were: 
 Heart rate changes were lower in patients with oral Clonidine as compared to 
the other two groups (However, Gabapentin group swings were less wider 
than the placebo group). 
 Systolic blood pressure, Diastolic blood pressure and the Mean arterial 
pressure changes were lower in patients with oral Clonidine compared to the 
other two groups (However oral Gabapentin swings were less wider than the 
placebo group) 
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 VAS scoring were much lower in patients with oral Gabapentin compared to 
the other two groups (Clonidine < placebo group). 
 Anxiety Scores were higher in patients with oral placebo compared to other 
two groups (oral Gabapentin > Clonidine) 
  Ramsay sedation scores were higher in patients with oral Gabapentin 
compared to other two groups (Clonidine > placebo) 
 The Fentanyl dosage need was considerably lower in patients with oral 
Gabapentin compared to other two groups (Clonidine < placebo) 
  
 95 
 
CONCLUSION 
This study demonstrates that a single oral dose of Gabapentin and Clonidine 
given pre-operatively, effectively reduces intubation response in elective laparoscopic 
cholecystectomy. Gabapentin is found to be associated with acceptable tachycardia in 
2/3rd of this group of patients, persisting for upto 20-30 minutes of intubation. 
Clonidine is found to be more effective in reducing intubation response compared to 
both Gabapentin and placebo group.  
 Both Gabapentin and Clonidine when given orally for pre-emptive analgesia 
reduced the post-operative pain scores and analgesic requirements in patients 
undergoing elective laparoscopic cholecystectomy. The incidence of nausea and 
vomiting were found to be least with Clonidine. Sedation is the only significant side 
effect observed with Gabapentin in our study. 
Thus from our study and from all our findings, both Gabapentin and 
Clonidine drugs were found to be effective as good pre-emptive analgesics in 
attenuating hemodynamic stress response to laryngoscopy and intubation, with added 
benefit of providing post-operative pain relief also. Clonidine was found to be 
slightly better than Gabapentin in attenuating hemodynamic stress response to 
laryngoscopy and intubation. Gabapentin was found to be slightly better than 
Clonidine in providing post-operative pain relief. 
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INFORMATION TO PARTICIPANTS 
 
Investigator: Dr. Kokila.C 
 
Name of the Participant: 
 
 Title: 
“A Prospective, randomized study comparing the Pre-emptive analgesic 
effects of oral Gabapentin with oral Clonidine on intubation response and 
postoperative analgesic requirement for patients undergoing Laparoscopic 
Cholecystectomy“ 
You are invited to take part in this research study. We have got approval from 
the IEC. Your are asked to participate because you satisfy the eligibility criteria. We 
want to compare and study the safety and efficacy of oral Gabapentin and oral 
Clonidine for intubation response and post-operative pain management in elective 
Laparoscopic Cholecystectomy  
 
What is the Purpose of the Research: 
To compare the analgesic efficacy of oral Gabapentin with Oral Clonidine on 
intubation response and post-operative analgesic requirement for patients undergoing 
Laparoscopic Cholecystectomy, based on 
Heart rate (HR), Systolic arterial pressure (SAP), diastolic arterial pressure 
(DAP), mean arterial pressure (MAP) were measured at baseline (3 min before 
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induction), just before laryngoscopy, and post-intubation (at 1, 3, 5, and 10 min after 
starting laryngoscopy). 
 
Post-operative VAS score  
 
Post operative opioid requirement 
 
Dosage of rescue analgesics 
 
The Study Design: 
75 Patients presenting for elective Laparoscopic Cholecystectomy were 
randomly assigned into three groups. 
GROUP A (Gabapentin ) : received a 900mg tablet orally 90 minutes before 
anaesthetic induction. 
 
GROUP B (Clonidine) : received a 0.2mg tablet orally 90 minutes before anaesthetic 
induction. 
 
GROUP C (placebo) : received a placebo capsule orally 90 minutes before 
anaesthestic induction. 
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Benefits 
The usage of Gabapentin and Clonidine when administered preoperatively, has 
significant reduction in intubation response, maintains better intra operative 
hemodynamics, reduces post-operative opioid requirement, thereby significantly 
reducing the adverse effects of opioids, causes excellent post-operative pain relief. 
Discomforts and risks 
May cause nausea, vomiting, drowsiness, headache, anaphylactic reactions. 
This intervention has been shown to be well tolerated as shown by previous studies. 
And if you do not want to participate you will have alternative of setting the standard 
treatment and your safety is our prime concern. 
All tests, medicine and medical services concerned with this research will be provided 
free of cost to the patient. 
 
Time : 
Date : 
Place : 
Signature / Thumb Impression of Patient 
Patient Name: 
 
 
Signature of the Investigator : ____________________________ 
Name of the Investigator : ____________________________ 
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PATIENT CONSENT FORM 
Study Title: 
“A Prospective, randomized study comparing the Pre-emptive analgesic 
effects of oral Gabapentin with oral Clonidine on intubation response and post-
operative analgesic requirement for patients undergoing Laparoscopic 
Cholecystectomy” 
 
Study Center:  
Institute of Anaesthesiology and Critical Care, 
Madras Medicalcollege, 
Chennai- 600003. 
 
Participant name :  Age:  Sex:  I.P.No: 
 
I confirm that I have understood the purpose of the above study . I have the 
opportunity to ask the  question and all my questions and doubts have been answered 
to my satisfaction. 
 I have been explained about the safety,advantage and disadvantage of the 
drugs. 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at anytime without giving any reason. 
I understand that investigator ,regulatory authorities and the ethical committee 
will not need my permission to look at my health records both in respect to current 
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study and any further research that may be conducted in relation to it, even if I 
withdraw from the study . I understand that my identity will not be revealed in any 
information released to third parties or published , unless as required under the law . I 
agree not to restrict the use of any data or results that arise from the study . 
 
 
Time:  
 
Date: Signature / thumb impression of patient  
 
Place: Patient name: 
 
Signature of the investigator: 
 
 Name of the investigator: 
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PROFORMA 
 
Date :      Roll no :    
Name :  
Age :    Ht:  Wt:  Sex:   IP No: 
Diagnosis : 
Surgical procedure : 
 
PRE OP ASSESSMENT: 
 
HISTORY :   
Any Co-morbid illness 
H/O Documented Difficult Airway 
H/O previous surgeries 
 
EXAMINATION :   CVS  :    Hb : 
RS  : 
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MEASURES OF STUDY OUTCOME: 
 
 HR SBP DBP MAP SPO2 
Baseline Parameters      
3 Min Before Induction      
During Induction      
During Intubation      
1 Min After Intubation      
3 Min After Intubation      
5 Min After Intubation      
10 Min After Intubation      
 
 HR SBP DBP MAP SPO2 
VAS 
Score 
Ramsay 
Sedation 
Score 
Anxiety 
Score 
Pre-operative         
Post – op 0 Hr         
Post – op 1st Hr         
Post – op 2nd Hr         
Post – op 4th Hr         
Post – op 6th Hr         
Post – op 8th Hr         
  
COMPLICATIONS IN INTRA OPERATIVE PERIOD: 
RESCUE ANALGESICS USED:  
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Master Chart 
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